New drug duo offers hope for advanced penile cancer patients
NCT ID NCT07384416
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs, QL1706 and lenvatinib, in people with advanced penile cancer that has already been treated. The goal is to shrink tumors and possibly make them removable by surgery. About 47 adults aged 18–80 will receive the drugs for up to a year, with the aim of controlling the disease and improving survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PENILE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Penis transplants could restore form and function for wounded warriors
- New drug combo targets HPV-Driven cancers in phase II trial
- Double antibody attack: early trial combines immune and Growth-Signal blockers against advanced cancers
- Triple immunotherapy attack shows promise against Hard-to-Treat HPV cancers
- Promising drug cocktail aims to shrink penile cancer before surgery